Background and objective: Combination long-acting β 2 -agonist/long-acting muscarinic antagonist (LABA/ LAMA) has demonstrated superior clinical outcomes over LABA/inhaled corticosteroid (ICS) in chronic obstructive pulmonary disease (COPD) patients; however, data from blinded randomized controlled trials on direct switching from LABA/ICS to LABA/LAMA are lacking. FLASH (Assessment of switching salmeterol/ Fluticasone to indacateroL/glycopyrronium in A Symptomatic COPD patient coHort) investigated if direct switch, without a washout period, from salmeterol/fluticasone (SFC) to indacaterol/glycopyrronium (IND/GLY) in COPD patients improves lung function and is well tolerated. Methods: In this 12-week, multicentre, double-blind study, patients with moderate-to-severe COPD and up to one exacerbation in previous year, receiving SFC for ≥3 months, were randomized to continue SFC 50/500 μg twice daily (bd) or switch to IND/GLY 110/50 μg once daily (od). Primary endpoint was pre-dose trough forced expiratory volume in 1 s (FEV 1 ) at Week 12. Results: In total, 502 patients were randomized (1:1) to IND/GLY or SFC. Patients switched to IND/GLY demonstrated superior lung function (pre-dose trough FEV 1 ) versus SFC at Week 12 (treatment difference (Δ) = 45 mL; P = 0.028). IND/GLY provided significant improvements in pre-dose trough forced vital capacity (FVC; Δ = 102 mL; P = 0.002) and numerical improvements in transition dyspnoea index (TDI; Δ = 0.46; P = 0.063). Rescue medication use and COPD assessment test (CAT) scores were comparable between groups. Both treatments had similar safety profiles.
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is one of the major causes of morbidity and mortality worldwide and predicted to be the third leading cause of death by 2020. 
SUMMARY AT A GLANCE
Direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone, without washout period, improved lung function in patients with moderateto-severe chronic obstructive pulmonary disease (COPD) with up to one exacerbation in the previous year without adverse consequences.
Long-acting bronchodilators (long-acting β 2 -agonist (LABA), long-acting muscarinic antagonist (LAMA) or the combination) are the cornerstone of treatment for all symptomatic patients with COPD, regardless of exacerbation history. 2 Indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily (od), a fixed-dose LABA/LAMA combination, has demonstrated superiority in improving lung function and reducing symptoms and exacerbations over the LABA/inhaled corticosteroid (ICS) salmeterol/fluticasone (SFC) 50/500 μg twice daily (bd) in head-to-head randomized controlled trials (RCT), and has demonstrated lower incidences of pneumonia and other adverse events (AEs). [3] [4] [5] Furthermore, the open-label CRYSTAL study has demonstrated that direct switch to IND/GLY from any LABA + ICS was safe and improved lung function and symptoms in COPD patients with moderate airflow limitation. 6 Apart from CRYSTAL, previous RCT comparing LABA/LAMA with LABA/ICS had a run-in period wherein all patients received the same baseline treatment. [4] [5] [6] Currently, there are no data available from blinded RCT on direct switching from LABA/ICS treatment to LABA/LAMA in symptomatic nonfrequently exacerbating COPD patients. FLASH (Assessment of switching salmeterol/Fluticasone to indacateroL/glycopyrronium in A Symptomatic COPD patient coHort) is the first randomized, double-blind, study to investigate the efficacy and safety of direct switch from the SFC 50/500 μg bd to IND/GLY 110/50 μg od, without a washout period, in symptomatic COPD patients with moderate-to-severe airflow limitation and up to one exacerbation in the previous year.
METHODS

Study design
FLASH was a 12-week, multicentre, randomized, double-blind, double-dummy, active-control, parallelgroup study (Fig. 1) . Patients who were receiving SFC 50/500 μg bd for at least 3 months were assessed for eligibility during a 14-day screening period, wherein open-label SFC was provided as the COPD treatment. After the screening period, eligible patients were directly randomized (1:1) to one of the two doubleblinded treatment arms: (i) IND/GLY 110/50 μg od and placebo for SFC or (ii) SFC 50/500 μg bd and placebo for IND/GLY. No drug washout period was allowed between the screening and randomization visit; the randomized patients either continued to receive SFC or switched to IND/GLY without a washout period. Detailed methodology is given in Appendix S1 (Supplementary Information).
The study was approved by institutional review boards or independent ethics committees at participating centres, and was performed according to Declaration of Helsinki and the Good Clinical Practice guidelines. All patients provided written informed consent.
Patients
Patients aged ≥40 years with moderate-to-severe COPD and up to one exacerbation in the previous year, who had been receiving treatment with SFC 50/500 μg bd for at least 3 months prior to screening, were included. SFC treatment had been decided by the patient's physician with full discretion of the appropriateness of this treatment. Detailed inclusion/exclusion criteria are provided in Appendix S2 (Supplementary Information).
Study objectives
The primary objective was to demonstrate superiority of IND/GLY 110/50 μg od compared with SFC 50/500 μg bd in pre-dose trough forced expiratory volume in 1 s (FEV 1 ) at Week 12.
Secondary objectives were to evaluate the effect of IND/GLY compared with SFC on pre-dose trough forced vital capacity (FVC), transition dyspnea index (TDI), COPD health status as measured by COPD assessment test (CAT) scores, mean daily use of rescue medication (number of puffs) and percentage of days without rescue medication use, safety and tolerability over 12 weeks.
Statistical analysis
A required sample size of 418 patients was calculated to detect pre-dose trough FEV 1 change of 70 mL with 90% power. Assuming a 15% drop out rate, 492 patients were planned to be randomized. Efficacy was assessed in patients included in full analysis set (FAS), which included all randomized patients who received at least one dose of the randomized study medication. Perprotocol set (PPS) included all FAS patients without any major protocol deviations. Safety set included all patients who received at least one dose of the study treatment.
Change from baseline in pre-dose trough FEV 1 and pre-dose trough FVC, TDI score and CAT score was analysed using analysis of covariance (ANCOVA) for repeated measures, including terms of treatment, baseline value, smoking status at baseline, region, visit, treatment by visit interaction and baseline value by visit interaction as fixed effects with centre nested within region as random effect. Percentage of patients with a clinically significant improvement in TDI (≥1) was analysed using a logistic regression model for repeated measures. Mean daily use of rescue medication (number of puffs) over 12 weeks of treatment was analysed using a linear mixed model, which included treatment, baseline mean daily number of puffs, smoking status at baseline and region as fixed effects with centre nested within region as a random effect. FAS was used for the analyses of the primary objective and all secondary efficacy variables. The statistical significance was shown for primary objective at P-value <0.05. There were no multiplicity adjustments for secondary objectives. Therefore, all P-values of secondary objectives were of a descriptive nature.
RESULTS
Patients
A total of 502 patients were randomized to the IND/GLY and SFC groups (251 patients in each group) across 60 centres from 11 countries, from 19 October 2015 to 4 May 2017 (Table S1 , Supplementary Information). Of these, 473 patients (94.2%) completed the study and 29 (5.8%) discontinued prematurely ( Baseline demographic characteristics were balanced between groups (Table 1) . Patients were predominantly male with mean age of 65 years, and 37.3% of patients were current smokers. In the year prior to study entry, 39.8% of patients had experienced one moderate or severe COPD exacerbation. The majority of patients Figure 2 Patient disposition. The FAS was used for the analysis of the primary endpoint. Patients who failed screening and were rescreened under a new patient number were only counted once. In total, 10 patients were re-screened, of whom 6 patients were randomized. The primary reasons for discontinuation are summarized as given by the investigator on the study completion of eCRF. eCRF, electronic case report form; FAS, full analysis set; GLY, glycopyrronium; IND, indacaterol; SFC, salmeterol/fluticasone.
were Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 group B (85.9%).
Pre-dose trough FEV 1
The primary objective of demonstrating superiority of IND/GLY over SFC in improving pre-dose trough FEV 1 was met. Patients switched to IND/GLY demonstrated superiority in mean pre-dose trough FEV 1 (treatment difference (Δ) = 45 mL, 95% CI: 5 to 84; P = 0.028) at Week 12 (Fig. 3A) . The estimated change from baseline in pre-dose trough FEV 1 was higher in PPS (Δ = 57 mL, 95% CI: 19 to 94; P = 0.003) than in FAS (Fig. 3B) . 
Safety and tolerability
Both treatments had comparable safety profiles (Table 2) . Fewer patients on IND/GLY reported COPD exacerbations as an AE (IND/GLY 10.1% vs SFC 13.2%). In total, 17 patients (IND/GLY: n = 10 (4.0%) and SFC: n = 7 (2.8%)) experienced AE that were suspected to be related to study drug.
During the study, 18 patients (9 patients (3.6%) in each group) experienced serious AE (SAE). Except atrial fibrillation (one patient in IND/GLY group (0.4%)), remaining events were not suspected to be related to study drug. The most frequent SAE were COPD exacerbations. Pneumonia was reported as an SAE in two cases (IND/GLY: 'aspiration pneumonia'; SFC: 'infectious pneumonia'). Two patients (one from each group) died during the study. The patient death in the IND/GLY group was attributed to 'sudden death' and in the SFC group it was attributed to 'myocardial infarction'. Neither death was suspected to be related to study medication. Another two deaths (one from each group) were reported after study completion. One patient from the IND/GLY group experienced fatal AE (attributed to penetrating aortic ulcer, aspiration pneumonia, and cerebral infarction) starting within 30 days after last dose of the study drug. One patient from the SFC group experienced fatal AE (cardiorespiratory arrest secondary to pneumonia and immunodeficiency) starting >30 days after last dose of the study drug. These fatalities were also not suspected to be related to study medications.
DISCUSSION
To the best of our knowledge, FLASH is the first double-blind RCT to evaluate a direct switch, without a washout period, from SFC to IND/GLY. Although the superiority of IND/GLY has been demonstrated in RCT, [3] [4] [5] evidence from direct switch from SFC is lacking. Unlike most clinical trials, in FLASH, IND/GLY was started immediately after stopping SFC and ICS washout was not allowed in order to mimic clinical practice.
FLASH met its primary objective, improving trough FEV 1 at Week 12 with IND/GLY in patients with moderate-to-severe COPD and a history of up to one exacerbation in the previous year. Significant improvement in trough FVC with IND/GLY and numerical improvement in dyspnoea as expressed by TDI were also demonstrated. The two treatments had comparable safety profiles.
FLASH adds to the body of evidence on the superiority of IND/GLY on lung function over SFC. [3] [4] [5] Improvement in trough FEV 1 of 45 mL is comparable with that seen in FLAME where pre-dose trough FEV 1 significantly improved with IND/GLY versus SFC by 62 mL at 52 weeks in COPD patients with moderate-to-very severe airflow limitation and ≥ 1 exacerbation in the previous year. 4 Similarly, CRYSTAL demonstrated improvement in trough FEV 1 of 71 mL versus LABA + ICS at 12 weeks in COPD patients with moderate airflow limitation. 6 The numerical differences in the degree of lung function improvement between FLASH and CRYSTAL may be due to differences in methodology, patient population and previous COPD medication. 4, 6 Other studies also demonstrated significant improvement in trough FEV 1 with IND/GLY at Week 12 in COPD patients. 3, 5 In recent analyses of data from previous RCT, greater efficacy in terms of lung function has been observed with LABA/LAMA combinations versus LABA/ICS and these findings have been largely driven by the IND/GLY versus SFC comparisons.
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The difference of 45 mL in FAS and 57 mL in PPS is lower than the proposed MCID of 100 mL for FEV 1 10 ; however, this MCID was proposed in the context of placebo-controlled trials. 11 In this study, IND/GLY was compared with the active treatment SFC; hence, the expected and observed change in trough FEV 1 was smaller than the MCID but still, in our opinion, of clinical importance. In AFFIRM, there were no significant differences in trough FEV 1 between aclidinium/formoterol 400/12 μg bd and SFC at Week 24. 12 In ENER-GITO, tiotropium/olodaterol (TIO/OLO) 5/5 μg od significantly improved trough FEV 1 by 58 mL compared with SFC after 6 weeks. 13 Evaluation of other measures of lung function demonstrated a significant improvement in trough FVC with IND/GLY versus SFC at Week 12, larger than the increase seen in trough FEV 1 . Similar improvements were observed in FVC in other studies comparing IND/GLY with SFC at Week 12.
3,5 Bronchoconstriction in COPD is associated with hyperinflation, 14 resulting in restriction of inspiratory capacity (IC) and FVC. Reduced hyperinflation from bronchodilators, evidenced by expansion of IC and increased FVC, has been described. 15, 16 A significant degree of reversibility was observed after administration of combined salbutamol and ipratropium. This is consistent with previous observations suggesting that a large proportion of COPD patients present significant bronchodilator reversibility, 17 although this has not been associated with long-term response to long-acting bronchodilators. 18 Moreover, any history of asthma was an exclusion criterion.
In FLASH, there was a numerical improvement in TDI score in patients who switched to IND/GLY. This result is numerically similar to those observed in previous RCT. 3, 5 In CRYSTAL, IND/GLY was associated with significantly improved TDI scores versus LABA + ICS after 12 weeks, albeit to a greater extent, perhaps due to the open-label design. 6 In BLAZE, the only randomized trial for IND/GLY that assessed improvements in dyspnoea as the primary endpoint, TDI was significantly higher with IND/GLY versus placebo and versus TIO 18 μg od after 6 weeks. 19 In AFFIRM, no significant differences in TDI scores were observed between aclidinium/formoterol versus SFC when analysing data stratified by prior ICS use or previous exacerbations. 12 In this study, CAT scores and rescue medication use were similar in both groups at Week 12. Again, similar results were obtained in LANTERN where use of rescue medication and total CAT scores after 26 weeks were comparable between IND/GLY and SFC. 5 Considering that a large population in FLASH study was Asian, we examined the large Asian cohort of FLAME, where no significant change in percentage of rescue medicationfree days was observed with IND/GLY versus SFC. 4, 20 Incidence of AE was comparable between the treatment groups, in line with other studies involving IND/GLY 4, 6 with no new safety signals emerging from the present study.
We acknowledge that the relatively short treatment duration in FLASH may be a limitation and may not clearly reflect the long-term efficacy or safety of study medications, especially in terms of effects of IND/GLY on exacerbations and risk of pneumonia with ICS. However, the 12-week duration of FLASH was sufficiently powered to assess lung function. Unlike most RCT, in clinical practice settings therapies are changed suddenly. The direct switch of treatment in FLASH reflects clinical practice and complements findings from RCT with washout periods. These results further reinforce the latest GOLD recommendations 2 that support the use of dual bronchodilation for symptomatic COPD patients and limit the use of steroid-containing therapies to specific patient types.
Additionally, the study population in FLASH was mainly GOLD group B, representing a substantial proportion of the COPD patient population that receives pharmacological treatment. Notably, the GOLD grouping used in this study is the same as in the recent GOLD 2018 recommendation. 2 Although the results of the FLASH study applies to a patient population with low exacerbation rates, the consistency between FLASH results and those of other studies, some of which extended up to 52 weeks, 4 validates the observations from FLASH and supports the use of IND/GLY over SFC for the management of most COPD patients in clinical settings. These results support current GOLD recommendation for LABA/LAMA being a preferred therapy for symptomatic COPD patients. 2 Recently published studies provide more information on patients who may benefit from the addition of ICS on top of LABA/LAMA. [21] [22] [23] Conclusively, in symptomatic COPD patients with moderate-to-severe airflow limitation and a history of up to one exacerbation in the previous year, a direct switch without a washout from previous treatment with open-label SFC to IND/GLY, resulted in improved predose FEV 1 and FVC compared with patients who continued to receive blinded SFC. The safety profiles of IND/GLY and SFC observed in this study were similar to previous studies, with the expected AE and no new safety signals being identified.
This study adds to the body of evidence that LABA/ LAMA is a preferred treatment option compared with SFC in patients with symptomatic COPD but low risk of exacerbations, further supporting current treatment recommendations.
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